论文部分内容阅读
目的探讨前列地尔治疗Ⅳ期糖尿病肾病的临床疗效。方法选取盘县人民医院2012年3月—2014年5月收治的54例Ⅳ期糖尿病肾病患者,将其随机分为对照组和试验组,各27例。对照组患者接受常规治疗,试验组患者接受前列地尔治疗,比较两组患者的临床治疗效果。结果试验组患者的治疗总有效率为85.2%,对照组为66.7%,两组差异有统计学意义(P<0.05);治疗后试验组患者血肌酐、尿微量清蛋白及尿蛋白水平低于对照组,差异有统计学意义(P<0.05)。结论前列地尔是一种较为有效且安全的Ⅳ期糖尿病肾病临床治疗药物。
Objective To investigate the clinical efficacy of alprostadil in the treatment of stage Ⅳ diabetic nephropathy. Methods 54 patients with stage Ⅳ diabetic nephropathy who were treated in Panxian People’s Hospital from March 2012 to May 2014 were selected and randomly divided into control group and experimental group, with 27 cases in each group. Patients in the control group received routine treatment, patients in the test group received alprostadil, and the clinical effects of the two groups were compared. Results The total effective rate was 85.2% in the trial group and 66.7% in the control group, with significant difference between the two groups (P <0.05). The serum creatinine, urine microalbuminuria and urine protein in the test group were lower than Control group, the difference was statistically significant (P <0.05). Conclusion Alprostadil is a more effective and safe clinical treatment of stage Ⅳ diabetic nephropathy.